U.S. President Donald Trump is expected to sign an executive order as soon as this week that would fast-track the reclassification of cannabis, NBC News reported on Tuesday, citing four people with di... ...

2 TORONTO--(BUSINESS WIRE)--Organigram Global Inc (NASDAQ: OGI) (TSX: OGI), (the "Company†or "Organigram†), Canada's #1 recreational cannabis company by market share, is pleased to announce record results for the fourth quarter and twelve months ended September 30, 2025 ("Q4 Fiscal 2025†or "Fiscal 2025"). All financial information in this press release is expressed in Canadian dollars ("$"). FOURTH QUARTER 2025 FINANCIAL HIGHLIGHTS FISCAL 2025 FINANCIAL HIGHLIGHTS FISCAL 2025 COMPANY HIGHLIGHTS 2 "Fiscal ...

No age group is taking up cannabis faster https://t.co/LdXBqdnjiE ...

Turkey isn't the only thing getting baked this Thanksgiving. Turns out today has become one of the biggest cannabis sale holidays of the year. Behind only April 20th, of course, that's 420.And this year, the industry is really cooking. I checked in with some popular brands. THC infused beverage maker can tells me November typically brings in a 40% month-over-month sales jump and that this year they're already pacing to beat that.Nowadays, another brand also seeing the holiday bump. Last November, sales spik ...

Well, move over Black Friday. Cannabis has carved out its own holiday shopping rush and it's called Green Wednesday. Our Brandon Gomez joins us with that story.Brandon, we were talking about this hit in advance and it kind of makes some sense. Hey, Carl. Yeah, that's right.We've been talking about the trend, but look, turkey isn't the only thing getting baked this Thanksgiving. Turns out today has become one of the biggest cannabis sale holidays of the year. Behind only April 20th, of course, that's 420.And ...

 October 20, 2025 – TheNewswire - Vancouver, B.C. – Herbal Dispatch Inc. (CSE: HERB) (“Herbal Dispatch” or the “Company”) is pleased to announce that in furtherance to its news releases issued on July 29, August 28, and September 3, 2025, the Company has closed its oversubscribed non-brokered private placement (the “Private Placement”), with the sale of 41,564,220 units (each a “Unit”) at a price of CAD$0.05 per Unit, for aggregate subscription proceeds of CAD$2,078,211. Each Unit subscribed for under the ...

Core Viewpoint - Canopy Growth Corporation has launched a new at-the-market equity program to raise up to $200 million in common shares, aimed at supporting strategic investments and working capital [1][2]. Group 1: Equity Program Details - The new equity program allows for the issuance and sale of up to $200 million in common shares across U.S. and Canadian markets, with Canadian sales capped at $50 million [2]. - The program is governed by an equity distribution agreement dated August 29, 2025, with BMO Nesbitt Burns Inc. and BMO Capital Markets Corp. as agents [3]. - The program will remain active until June 5, 2027, or until the full $200 million is raised, with the Canadian portion ending earlier on July 5, 2026, or upon reaching its $50 million cap [3]. Group 2: Company Overview - Canopy Growth Corporation operates in the cannabis industry, producing and selling cannabis, hemp, and related products across Canada, Germany, and Australia [4]. - The company operates through four segments, including Canada Cannabis and International Markets, offering a variety of products such as dried flower, pre-rolls, edibles, vapes, oils, and concentrates [4]. - Canopy Growth markets its products under multiple brands, including Tweed, 7ACRES, Spectrum Therapeutics, Storz & Bickel, Wana, and DOJA [4].

Industry Concerns & Risks - The industry expresses concern that Berkshire Hathaway may have made a "bad mistake" in a certain investment, though the specific investment is not named [1] - The industry views cannabis investments as a "major bad bet" [1] - GLP-1 drugs are seen as negatively impacting the beer industry [1] - Tariffs on bottles and cans are directly affecting the industry [1] Company Performance & Activist Involvement - A company, described as a "poster boy," is perceived by many as having reached its lowest point, but the industry suggests a need to recognize underlying issues [2] - Elliott, an activist investor, previously engaged with a company (possibly the "poster boy" mentioned earlier) but has since exited, raising questions about the potential for improvement [2] Competitive Landscape & Valuation - Brown-Forman's performance is described as severely underperforming, with its stock price hitting new lows [3] - Diageo is considered overvalued by the industry [3]

Core Argument - The presentation explores the dual nature of drugs, examining both their potential therapeutic benefits and their inherent risks of addiction [3][5] - It emphasizes that the positive and negative effects of drugs are distinct and arise through different pathways [5] - The speaker advocates for understanding the balance between the benefits and risks of substances, particularly in the context of medication development [28] Drug Use & History - Throughout history, substances like alcohol, ayahuasca, cannabis, coca, and opium have been used for treatments, rituals, and recreation [7] - Opium and its derivatives, such as morphine, are potent analgesics used for pain management but also contribute to addiction epidemics [8][9] - Cocaine, derived from coca leaves, has been used to combat fatigue and altitude sickness, but it is a powerful and addictive psycho-stimulant [11][12] - Cannabis, the most widely consumed illicit drug in Spain and surrounding countries, is used to treat pain and epilepsy, and to alleviate chemotherapy side effects, but it can also lead to addiction and psychosis in young individuals [13][14] Addiction & the Brain - Addiction is framed as a disease resulting from drugs hijacking the brain's motivation and reward circuits, leading to a loss of control and altered behavior [19][20] - The presentation highlights that addiction can cause individuals to lose their capacity for survival and can lead to other illnesses, such as schizophrenia from cannabis use and strokes from cocaine use [20][21] - Alcohol, a commonly consumed substance during celebrations, is also identified as a drug of abuse, emphasizing the importance of responsible consumption and delaying initial use among young people [24][25] Research & Therapeutic Potential - The key to harnessing the beneficial effects of drugs while minimizing harm lies in thorough research to understand their characteristics, appropriate dosages, and potential interactions [26][27][28] - Psilocybin, a hallucinogenic substance, is presented as an example of a drug with potential antidepressant effects, particularly for individuals with treatment-resistant depression, highlighting the importance of assessing the benefit-risk ratio [29][30][31] - The presentation concludes that the paths of drugs and medicines diverge, with drugs leading to loss of control and disease, while medicines offer healing and treatment through innovation and research [33][34]

Publicly traded cannabis company Dogecoin Cash Inc. is embracing the real DOGE after previously stockpiling a derivative meme coin. https://t.co/iZdHX4S3UD ...